MedPath

BlueSky Immunotherapies GmbH

🇦🇹Austria
Ownership
Private
Employees
-
Market Cap
-
Website
https://www.blueskyvaccines.com

Clinical Trials

6

Active:1
Completed:2

Trial Phases

1 Phases

Phase 1:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (100.0%)

Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer

Phase 1
Recruiting
Conditions
Oropharyngeal Squamous Cell Carcinoma (SCC)
Interventions
First Posted Date
2024-09-10
Last Posted Date
2024-09-10
Lead Sponsor
BlueSky Immunotherapies GmbH
Target Recruit Count
12
Registration Number
NCT06589609
Locations
🇦🇹

Medical University Vienna, Vienna, Austria

Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

Phase 1
Recruiting
Conditions
HPV Infection
HPV-Related Cervical Carcinoma
Interventions
First Posted Date
2023-04-26
Last Posted Date
2025-02-14
Lead Sponsor
BlueSky Immunotherapies GmbH
Target Recruit Count
20
Registration Number
NCT05829629
Locations
🇸🇰

Univerzitná nemocnica Bratislava, Bratislava, Slovakia

BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects

Completed
Conditions
Safety Issues
HPV Infection
First Posted Date
2020-08-27
Last Posted Date
2025-02-13
Lead Sponsor
BlueSky Immunotherapies GmbH
Target Recruit Count
25
Registration Number
NCT04528407
Locations
🇦🇹

University of Vienna, Vienna, Austria

Study of FluBHPVE6E7 in HPV-16 Infected Women

Phase 1
Completed
Conditions
HPV Infection
First Posted Date
2020-07-29
Last Posted Date
2023-06-26
Lead Sponsor
BlueSky Immunotherapies GmbH
Target Recruit Count
28
Registration Number
NCT04490512
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.